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As the role of microRNA in all aspects of biology continues to be unraveled, the interplay
betweenmicroRNAs and human disease is becoming clearer. It should come of no surprise
thatmicroRNAsplay amajor part in the outcomeof infectious diseases, since earlywork has
implicated microRNAs as regulators of the immune response. Here, we provide a review
on how microRNAs inﬂuence the course of mycobacterial infections, which cause two of
humanity’s most ancient infectious diseases: tuberculosis and leprosy. Evidence derived
from proﬁling and functional experiments suggests that regulation of speciﬁc microRNAs
during infection can either enhance the immune response or facilitate pathogen immune
evasion. Now, it remains to be seen if the manipulation of host cell microRNA proﬁles can
be an opportunity for therapeutic intervention for these difﬁcult-to-treat diseases.
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INTRODUCTION
The burden of mycobacterial infection on human health and
disease simply cannot be understated, due mostly to Mycobac-
terium tuberculosis, the etiological agent of tuberculosis. Globally,
it is estimated that two billion people are infected with M.
tuberculosis, of which 10% develop active tuberculosis resulting
in nearly 1.4 million deaths per year. Although there is cur-
rently a vaccine for tuberculosis, the attenuated M. bovis strain
bacille calmette-guerin (BCG), it is considered to be largely inef-
fective (Orme, 2013). Another species of Mycobacterium that
has made a signiﬁcant impact on human health is M. lep-
rae, the etiological agent of leprosy. Also known as Hansen’s
disease, leprosy has affected human history for thousands of
years both medically and sociologically due to the social stigma
associated with those afﬂicted, at times resulting in forced segre-
gation of infected individuals into isolation colonies. Fortunately,
according to the WorldHealth Organization (WHO), over 14mil-
lion leprosy patients were cured in the last 20 years due to
distribution of multidrug therapy treatment. Other mycobacte-
rial species such as M. avium complex also cause opportunis-
tic infections in immunocompromised individuals, which is a
serious problem for the clinical management of HIV-infected
patients.
Only through intensive human effort into research and clinical
care have we witnessed a decrease in the disease burden caused
by pathogenic mycobacteria; however, incidence of multidrug
resistant and extensively drug resistant tuberculosis (MDR-TB
and XDR-TB, respectively) is on the rise, and there are even
reported cases of totally drug resistant tuberculosis (TDR-TB;
Velayati et al., 2009). These emerging infections dictate a need for
new avenues of treatment, such as host-targeted immunothera-
pies, which leads us to the question: how are these disease-causing
mycobacterial species,M. tuberculosis andM. leprae, able to escape
our immune defenses? Here we will review the studies that have
examined the function of microRNAs in mycobacterial infections
and what we have learned about these diseases by going beyond
proﬁling.
LEARNING FROM LEPROSY
While the global incidence of leprosy has been dramatically
reduced, research on the host defense against M. leprae and
disease pathogenesis continues to provide insight into which
immune pathways are essential for containment of mycobacte-
rial infections. Leprosy is a powerful model to study the human
immune response because it presents as a spectrumwhere the clin-
ical manifestations correlate with the level of immune response
to the pathogen, contributing to host defense or pathogene-
sis (Ridley and Jopling, 1966). At the ends of the spectrum
are the tuberculoid (T-lep) and lepromatous (L-lep) forms, in
which the infection is self-limited or disseminated, respectively
(Figure 1). Unlike tuberculosis, which manifests primarily in
the lungs, leprosy presents as granulomatous lesions in the
skin, which can be obtained with minimal risk to the patient.
Comparisons of T-lep and L-lep skin lesions have yielded impor-
tant information regarding the adaptive and innate immune
responses needed for protection against M. leprae infection.
Skin lesions from T-lep patients exhibit an adaptive immune
response characterized by Th1 cytokines (Salgame et al., 1991;
Yamamura et al., 1991), Type II interferon (IFN) proﬁle (Teles
et al., 2013), and an innate immune response characterized by
macrophages programmed to express the vitamin D-mediated
antimicrobial pathway (Montoya et al., 2009). In contrast, L-lep
lesions are typiﬁed by an adaptive immune response char-
acterized by Th2 cytokines (Salgame et al., 1991; Yamamura
et al., 1991), Type I IFN proﬁle (Teles et al., 2013), and an
innate immune response characterized by macrophages pro-
grammed to express enhanced phagocytic activity (Montoya et al.,
2009).
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FIGURE 1 |The spectrum of leprosy. Characteristics of the innate and adaptive immune responses in either end of the leprosy spectrum.
microRNAs IN LEPROSY LESIONS – STARTING WITH
EXPRESSION PROFILING
As knowledge on the role of microRNAs in human condi-
tions, such as cancer, cardiovascular disease, neurodevelopmental
diseases, and autoimmune diseases continues to accumulate
(Ardekani and Naeini, 2010), evidence that microRNAs may
also be involved in mycobacterial infections is similarly build-
ing. Expression proﬁling experiments revealed 13 microRNAs
were more highly expressed in L-lep vs. T-lep lesions; in con-
trast, only two microRNAs were more highly expressed in T-lep
vs. L-lep lesions (Liu et al., 2012). mRNA targeting analysis of
the microRNA species enriched in L-lep lesions demonstrated a
signiﬁcant preferential targeting of genes known to be impor-
tant in host defense against intracellular pathogens, such as
Th1-related genes (IFN-γ, IL12A, and CD40LG). In particular,
hsa-mir-21, the most highly expressed microRNA in the L-lep
lesions, is conﬁrmed to target multiple genes (CYP27B1 and
IL1B) in the vitamin D antimicrobial pathway, a key pathway in
macrophage antimicrobial defense againstmycobacterial infection
(Liu et al., 2006, 2012). To understand how hsa-mir-21 can inﬂu-
ence the outcome of mycobacterial infection, we will ﬁrst discuss
the role of the vitamin D pathway in macrophage antimicrobial
defense.
THE VITAMIN D ANTIMICROBIAL PATHWAY AND
MYCOBACTERIAL INFECTION
Detection of M. leprae (Krutzik et al., 2003) and M. tuberculosis
(Brightbill et al., 1999) by innate immune cells such as monocytes
and macrophages is mediated, in part, by the pattern recognition
receptor heterodimer, Toll-like receptor 2 and 1 (TLR2/1). Acti-
vation of TLR2/1 on monocytes results in the induction of the
vitamin D receptor (VDR) and CYP27B1 in an IL-15-dependent
manner (Liu et al., 2006; Krutzik et al., 2008). The CYP27B1 gene
product (CYP27b1), a cytochrome P450 hydroxylase, is respon-
sible for the conversion of the circulating prohormone form of
vitamin D (25-hydroxyvitamin D3, 25D) into its active hormone
form (1,25α-dihydroxyvitamin D, 1,25D). If the extracellular
concentration of 25D is sufﬁcient, CYP27b1 will convert 25D
into 1,25D, resulting in activation of the VDR and expression
of antimicrobial peptides cathelicidin (CAMP) and human beta
defensin-2 (DEFB4; Liu et al., 2009).
Convergence of IL-1β signaling and vitamin D transcrip-
tional activation is required for the TLR-induced expression
of DEFB4 (Liu et al., 2009). Triggering of TLR2/1 was found
to modulate IL-1β activity and increase the cell’s responsive-
ness to IL-1β by simultaneously (i) inducing IL-1β secretion,
(ii) increasing expression of cell surface IL-1 receptor 1 (IL-
1R1), and (iii) decreasing the baseline secretion of IL-1 receptor
antagonist (IL-1RA; Liu et al., 2009). Loss of CAMP or DEFB4
expression, as well as blockage of the vitamin D pathway,
ablated the TLR2/1-induced antimicrobial activity, implicating
the vitamin D antimicrobial pathway as a critical part of the
innate immune response against M. tuberculosis (Liu et al., 2006,
2009). Interestingly, although TLR2/1 activation of monocytes
induces antimicrobial activity against M. tuberculosis infection
(Thoma-Uszynski et al., 2001; Liu et al., 2006, 2012), it was
insufﬁcient to trigger antimicrobial activity against M. leprae
infection (Liu et al., 2012). The differential ability of TLR2/1 acti-
vation to induce antimicrobial activity against M. tuberculosis
or M. leprae negatively correlated with the induction of hsa-
mir-21 during infection, where M. leprae induced hsa-mir-21,
but M. tuberculosis did not (Liu et al., 2012). When consid-
ered together with the distinct microRNA expression proﬁles in
leprosy lesions, these data are highly suggestive that infection-
induced microRNA expression could regulate the macrophage
innate immune response to the pathogen as a potential evasion
mechanism.
THE ROLE OF hsa-mir-21 IN ANTIMICROBIAL ACTIVITY
AGAINST MYCOBACTERIA
The ability of hsa-mir-21 to alter the outcome of infection was
conﬁrmed through functional studies. Transfection of hsa-mir-21
into human monocytes results in the reduction of TLR2/1-
stimulated expression of IL1B, CYP27B1, CAMP and DEFB4
and enhancement of the TLR2/1-stimulated immune-inhibitory
cytokine, IL10. Conversely, knockdown of hsa-mir-21 during
M. leprae infection of human monocytes results in enhanced
expression of IL1B, CYP27B1, CAMP and DEFB4, as well as a
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decrease in IL10 (Liu et al., 2012). One effect of the cumulative
hsa-mir-21-mediated regulation of the cellular gene expression
was ultimately control of the TLR2/1 antimicrobial activity against
the infection. The TLR2/1-triggered antimicrobial activity against
M. tuberculosis was ablated by hsa-mir-21; in contrast, block-
ing hsa-mir-21 during M. leprae infection resulted in rescue
of TLR2/1-induced antimicrobial activity. In addition, miR-21
inhibits IL-12p35 expression, a subunit in a major Th1 driv-
ing cytokine (Lu et al., 2009), and enhances IL-10, a major
Th2 driving cytokine (Sheedy et al., 2010; Liu et al., 2012). By
inhibiting the vitamin D antimicrobial pathway and skewing the
Th1 vs. Th2 T-cell response in leprosy, hsa-mir-21 could be a
major determinant of the clinical presentation of an infected
individual.
THE ROLE OF microRNAs DURING MYCOBACTERIAL
INFECTION OF MACROPHAGES
The clinical presentation of tuberculosis, like leprosy, can be
considered a spectrum with active disease and latent infection
at the opposing ends of the spectrum (Wu et al., 2012b). How-
ever, comparing polar ends of the tuberculosis spectrum at
the site of infection is immensely difﬁcult due to the inva-
sive nature of collecting lung tissue, especially from latently
infected individuals. An alternative approach is to compare infec-
tion by virulent and non-virulent mycobacteria or infected and
uninfected cells using in vitro and in vivo systems. Human
macrophages infected with virulent M. tuberculosis yields high
hsa-miR-125b and low hsa-miR-155 expression when compared
to infection with the non-virulent M. smegmatis (Tili et al.,
2007; Rajaram et al., 2011). This dichotomy of microRNA
expression inﬂuences the induction of TNF-α, given that miR-
125b binds and destabilizes TNF-α mRNA (Tili et al., 2007),
whereas miR-155 enhances TNF-α production (O’Connell et al.,
2009; Bala et al., 2011). Furthermore, transfection of mouse
macrophages with miR-155 results in decreased M. tubercu-
losis intracellular survival (Kumar et al., 2012). It is possible
that miR-155 alters antimicrobial activity through regulation
of two critical processes for protective immunity: macrophage
apoptosis (Ghorpade et al., 2012) and autophagy (Wang et al.,
2013).
Another microRNA, miR-142-3p, is also differentially regu-
latedby virulent andnon-virulentmycobacteria.When comparing
M. tuberculosis to M. smegmatis infection, miR-142-3p is up reg-
ulated rapidly (peaking at 1 h for mouse macrophages and 4 h
for human macrophages; Bettencourt et al., 2013), but down reg-
ulated at a later stage of the infection (24 h post-infection in
mouse macrophages; Martinez et al., 2013). Early induction of
miR-142-3p interfered with phagocytosis, a required cellular pro-
cess for the macrophage antimicrobial response, via targeting
the mRNA of the actin binding protein N-WASP (Bettencourt
et al., 2013). This disparity between regulation of miR-142-3p
at early and late time points by M. tuberculosis may be a reﬂec-
tion of the pathogen’s ability to elicit microRNAs that counteract
the sequential stages of the macrophage response. A separate
study supports the hypothesis that time-sensitive regulation of
microRNA can have a signiﬁcant impact on the outcome of
infection by showing that in contrast to virulent M. tubercu-
losis, infection with the non-virulent M. bovis BCG results in
early down regulation of mmu-miR-142-3p (Xu et al., 2013).
Decreased expression of mmu-miR-142-3p leads to increased
expression of target gene IRAK-1, an inhibitor of TLR signaling
(Ghorpade et al., 2012). Therefore, the loss of miR-142-3p would
enhance recognition of the infection and induction of antimi-
crobial activity for M. bovis BCG compared to M. tuberculosis
infection.
While control of the TLR response early during infection may
impair detection thus beneﬁting the pathogen, multiple microR-
NAs targeting TLR signaling are also induced later in infection.
M. bovis BCG infection of mice results in enhanced expression of
mmu-miR-31, mmu-miR-150, and mmu-miR-146a. In contrast,
the human homolog of the same microRNAs are signiﬁcantly
lower in the peripheral blood mononuclear cells (PBMCs) of
tuberculosis patients compared to healthy controls (Ghorpade
et al., 2013), suggesting a role for these microRNAs in control
of chronic inﬂammation. Through targeting the TLR signaling
cascade, miR-31, miR-150, and mir-146a (Taganov et al., 2006;
Ghorpade et al., 2013) may dampen the uncontrolled inﬂamma-
tion that leads to tissue damage, a major cause of pulmonary
morbidity and mortality in tuberculosis (Lazar-Molnar et al.,
2010). Thus, the microRNA proﬁle of the macrophage during
and after infection can have a signiﬁcant impact on the outcome of
infection and disease pathogenesis based on the immune pathways
targeted by the regulated microRNAs.
THE ROLE OF microRNAs DURING MYCOBACTERIAL
INFECTION – MORE THAN JUST MACROPHAGES
While macrophages are the target cell of mycobacterial infection,
they are not the only immune cell type involved and inﬂuenced by
microRNAs during infection. Critical at the interface of the innate
and adaptive immune responses, the dendritic cell (DC) has the
ability to activate and polarize T-cell responses, which is subject
to regulation by microRNAs. Induction of mir-99b by infection
of DCs with M. tuberculosis inhibits TNF-α production, whereas
knockdown of mir-99b leads to a decrease in bacterial burden
(Singh et al., 2013). Furthermore, infection of mouse DCs with
M. bovis BCG results in higher levels of miR-146a compared to
M. tuberculosis, thereby inhibiting the DC’s ability to differentiate
Th17 T-cells, an essential component for optimal vaccine efﬁcacy
(Chatterjee et al., 2011).
T-cells are also inﬂuenced by microRNAs during infection
despite not being permissive cellular hosts formycobacteria. Infec-
tion of mice with M. bovis BCG results in decreased expression of
mmu-miR-29 in T-cells which targets and down regulates the crit-
ical Th1 cytokine IFN gamma (IFN-γ; Ma et al., 2011). Ablation
of miR-29 in mice renders them more resistant to both M. bovis
BCG and M. tuberculosis infections (Ma et al., 2011), suggesting
that induction of miR-29 in T-cells during infection is a facilitator
of bacterial virulence. There is also evidence that hsa-miR-181a
may inﬂuence T-cell responses during leprosy due to its abil-
ity to dampen T-cell activation (Li et al., 2007). For that reason,
lower levels of hsa-miR-181a in T-cells derived from leproma-
tous vs. tuberculoid patients (Kumar et al., 2011) may explain the
prevalence of T-cell hyporesponsiveness in lepromatous leprosy
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patients, a hallmark of disease progression (Kumar et al., 2011).
Based on these studies, it is apparent that microRNA regulation
during mycobacterial infection can affect multiple cell types and
have wide ranging effects on the systemic immune system bymod-
ulating both the innate and adaptive immune responses to the
pathogen.
REGULATION OF GENE EXPRESSION PROFILES IN M. avium
INFECTION BY microRNAs
While the studies above unequivocally support the idea that a
single microRNA regulated during mycobacterial infection can
inﬂuence the resulting immune response by targeting key genes, it
was unclear whether the overall microRNA proﬁle and its cumu-
lative targets could alter the gene expression proﬁle of the infected
cell in a concertedmanner. An integratedmicroRNA-mRNA anal-
ysis of infected human macrophages helped provide insight into
the cumulative impact of microRNA regulation during infec-
tion. MicroRNA and mRNA expression proﬁles of macrophages
infected with M. avium subsp. hominissuis were obtained, and
microRNAs and mRNAs with negatively correlated expressions
were mapped onto a gene network and overlapped with target
predictions (Sharbati et al., 2011). The analysis revealed multi-
ple immune pathways potentially targeted by the conglomeration
of multiple infection-induced microRNAs, including: apopto-
sis, cytokine and inﬂammatory response, and NF-κB activation
(Sharbati et al., 2011).
There appears to be a concerted regulation of the apoptosis
pathway during M. avium subsp. hominissuis infection. Two
microRNAs inducedduring infection, hsa-miR-29a and let-7e, tar-
get and inhibit the pro-apoptotic caspase 3 and caspase 7 networks
(Sharbati et al., 2011). Down regulation of these caspase pathways
promotes an anti-apoptotic macrophage state, which is beneﬁ-
cial for bacterial survival. In addition, the pro-apoptotic tumor
suppressor protein p53 (TP53) is potentially targeted by let-7e
and miR-886-5p, microRNAs also up regulated during M. avium
subsp. hominissuis infection (Sharbati et al., 2011). Whether reg-
ulation of TP53 expression through microRNA expression during
infection can impact apoptosis remains to be seen. Taken together
the data from this study indicates that the globalmicroRNAproﬁle
induced during infection could dictate the gene expression proﬁle
of the host cell. Hence, it would be of beneﬁt for pathogens to
induce microRNAs that target immune pathways and down regu-
late microRNAs that perpetuate the immune response to facilitate
immune evasion during infection.
microRNA SIGNATURES IN TUBERCULOSIS
There has been signiﬁcant interest in identifying a microRNA sig-
nature of tuberculosis to provide diagnostic biomarkers and new
avenues for studying the immune response. Multiple microar-
rays have been performed on samples derived from tuberculosis
patients, ranging from PBMCs, pleural ﬂuid mononuclear cells
(PFMCs), pooled serum, and even PBMCs stimulated with
Table 1 | Summary of microRNAs and their impact during infection.
microRNA Cell type Expression level Target(s) Function
hsa-mir-21 (human) Skin lesions,
macrophages, monocytes
↑ L-lep vs. T-lep lesion
↑ M. leprae infection
CYP27B1, IL1B,
IL-12p35, PDCD4
Inhibition of antimicrobial activity
hsa-miR-125b
(human)
Macrophages ↑ M. tuberculosis vs. M. smegmatis
infection
TNF-α Possible subversion of host
immunity
miR-155 (human and
mouse)
Macrophages ↑ M. smegmatis vs. M. tuberculosis
infection
SHIP1 Enhancement of TNF-α, and
decreased M. tb intracellular
survival
miR-142-3p (human
and mouse)
Macrophages ↑ M. tuberculosis vs. M. smegmatis
infection (early)
↓ BCG vs. M. tuberculosis infection
(late)
N-WASP, IRAK-1 Disruption of phagocytosis, altered
TLR signaling
miR-99b (human and
mouse)
Dendritic cells ↑ M. tuberculosis infection TNF-α Increased bacterial burden
miR-146a (mouse) Dendritic cells ↑ BCG vs. M. tuberculosis infection IRAK-1, TRAF6 Suppression of IL-6, IL-1B, and
TNF-α expression and inability to
promoteTh17 cells
miR-29 (mouse) T cells ↓ BCG-infected mice IFN-γ Regulation of Th1 responses
hsa-miR-181a
(human)
T cells ↓T-lep vs. L-lep patients SHP2 DampensT cell activation
hsa-miR-29a (human) Macrophages ↑ M. avium infection Caspase 3 Promotes an anti-apoptotic state
hsa-let-7e (human) Macrophages ↑ M. avium infection Caspase 7 Promotes an anti-apoptotic state
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mycobacteria or mycobacterial ligands ex vivo. While a deﬁnitive
microRNA signature has yet to be determined, three microRNAs
with higher expression in active tuberculosis patients compared
to healthy controls have been positively evaluated for use as a
biomarker: miR-155 and miR-155* in stimulated PBMCs (Wu
et al., 2012a) and miR-29a in pooled serum (Fu et al., 2011).
In addition to expression analysis, microRNA single nucleotide
polymorphism (SNP) analysis has revealed a correlation between
SNPs in miR-146a (rs2910164) and miR-499 (rs3746444) and
increased pulmonary tuberculosis susceptibility in certain popu-
lations (Li et al., 2011). More work is required before microRNAs
can be integrated into clinical diagnostics and care for tuberculosis
patients.
CONCLUSION
The studies presented here support a role for regulation of
microRNA in mycobacterial infection and disease. Differential
expression of microRNAs in self-limiting vs. progressive infec-
tions or non-virulent vs. virulent infections illustrates the ability
of speciﬁc microRNAs present during infection to inﬂuence
the outcome of infection (Summarized in Table 1). Factors
that determine whether the microRNA expression proﬁle dur-
ing infection favors or targets the immune response when the
host cell and Mycobacterium are engaged could be a key point
in determining the outcome of the infection. As more insight
is gathered on (i) the functional consequences of microRNAs
regulation during mycobacterial infections, (ii) how the genes
and pathways they target facilitate the immune response and iii)
how they are regulated by the pathogens, an opportunity for
host microRNA-directed therapeutic intervention may present
itself.
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